HealthTech startup Aeon raises €8.2 million to scale its AI preventive health platform

Swiss health tech company Aeon, launched in 2024, has raised €8.2 million in a Seed funding round to advance its development of the world’s most sophisticated platform for early detection and preventive healthcare.

The round was led by London-based venture capital firm Concentric, with additional backing from Calm/Storm Ventures, GoHub Ventures, Kadmos Capital, EWOR, and renowned Swiss super angel investor Daniel Gutenberg—famous for supporting 12 unicorns, including AirBnB, Facebook, and SumUp.

Aeon combines full-body MRI, advanced blood biomarkers, and genetic insights into a comprehensive 60-minute check-up. This enables the early detection and prediction of more than 500 diseases and health risks, with results reviewed by board-certified physicians and discussed directly with a radiologist. So far, Aeon has achieved a 0% false positive rate in clinical-grade follow-ups—a key differentiator in a field often challenged by overdiagnosis and avoidable procedures.

“We’re redefining preventive care by shifting it from reactive checks to proactive, personalized health management. Our approach goes beyond early disease detection—we’re tackling one of preventive medicine’s biggest challenges: false positives. Every customer receives a tailored risk profile, along with a clear, medically grounded plan to monitor and reduce their health risks over time.” - said Tim Seithe, Aeon’s founder and CEO.

The newly secured funding will support Aeon’s expansion across Switzerland, Germany, and the UK, with additional international markets on the horizon. It will also support the acceleration of partnerships with insurers and employers to increase accessibility and affordability, while advancing Aeon’s multi-modal AI platform for earlier and more accurate diagnostics. As part of its growth, Aeon plans to open over 10 new locations in the coming months, scaling its clinical network.

‍